Renin-guided Hemodynamic Management in Patients With Shock

Shock is a common cause of death among patients admitted to intensive care units. Acute kidney injury (AKI) frequently occurs in patients with shock (3, 4). Maintaining adequate perfusion pressure and oxygen delivery is crucial in the hemodynamic management of shock (5). Several randomized controlled trials have evaluated the effect of various hemodynamic protocols treating shock patients with a "one size fits all" approach. However, such protocols did not reduce mortality (6-8). The task force of the surviving sepsis campaign identified the personalization of sepsis resuscitation as a research priority (9). Moreover, a large RCT showed that personalizing blood pressure targets reduced the risk of postoperative organ dysfunction in patients undergoing major surgery (10). These findings suggest that applying individualized hemodynamic strategy may optimize shock treatment and potentially improve outcomes (11).

Recent studies have investigated renin as a novel marker of tissue hypoperfusion in critically ill patients. While serum lactate level has been the most common and validated marker for tissue hypoperfusion (12), several studies are now suggesting that renin may predict mortality better than lactate in critically ill patients (13, 14). Notably, relative renin increase is associated with adverse clinical outcomes and shock reversal has been shown to decrease renin concentration (15).

The investigators aim to perform the Randomized Evaluation of persoNalized hemodynamIc maNagement based on serum renin concentration (RENIN) trial to test the hypothesis that renin-guided hemodynamic management can reduce a composite of mortality and acute kidney injury (AKI) progression during the hospital stay in patients requiring vasopressors compared with usual care.

Inclusion criteria

• ≥18 years old
• Admitted to an intensive care unit (ICU)
• Requiring norepinephrine infusion at any dose to maintain a mean arterial pressure (MAP) of ≥65 mmHg after initial fluid resuscitation
• Expected to stay in the ICU for at least 24 hours
• Written informed consent from the patient him-/herself or the patient's next of kin as requested by the ethics committee.

Exclusion criteria

• Pregnancy
• Refused informed consent
• Current enrollment into another randomized controlled trial that does not allow concomitant enrollment
• Requiring vasopressors for >12 hours before the enrollment
• Renal failure with an imminent need for renal replacement therapy (RRT)
• Intention to use RRT by clinical judgment despite lack of urgent clinical indication
• AKI stage 2 and 3 at enrollment according to the KDIGO criteria
• Prior enrollment in this study
• Severe liver disease (Child-Pugh score >7 points)
• Chronic kidney disease (CKD) equal to or worse than CKD stage IV (eGFR <30 mL/min/1.73 m2)
• History of kidney transplant
• Any condition explicitly requiring a higher or lower blood pressure target according to clinical judgment